Local business leaders, elected officials, scientists and scholars attended the 2017 BioHealth Capital Region Forum at the campus of MedImmune in Gaithersburg on April 19 and 20th. The forum focuses on the biotechnology cluster in Maryland, Virginia, and Washington, D.C., which is working collaboratively to become a top three biotech hub in the United States by 2023.
The Maryland Life Sciences Advisory Board (LSAB) was created by the legislature in 2007 to assist in maintaining Maryland’s preeminence in the life sciences industry. Comprised of 18 members, the Board includes the Secretary of the Maryland Department of Commerce, a representative designated by the Maryland Technology Development Corporation (TEDCO), and 16 members appointed by the Governor.
Say hello to Techweek.
The tech conference and festival company that currently hosts annual events in eight cities — including Chicago, New York, Los Angeles, Toronto and Dallas — will expand to the District this fall, according to an exclusive interview with Techweek CEO Amanda Signorelli.
Noble Life Sciences, a full service, GLP (Good Laboratory Practice)-compliant and non-GLP preclinical contract research organization (CRO), today announced that its Board of Directors has appointed Srujana Cherukuri as Chief Executive Officer (CEO) effective immediately. The board also announced that Dr. Cherukuri is now majority owner of Noble Life Sciences.
“With the acquisition of Spring Valley Laboratories, Noble Life Sciences has grown from a contract research organization offering in vivo drug services in small animals to a full service CRO offering services for the development of drugs, devices, and vaccines in a range of large and small animals,” said Ken Carter, Chairman of the Board. “Because the integration of Spring Valley Laboratories is complete, now is the right time to appoint a CEO who will continue Noble’s growth. Dr. Cherukuri was key to the successful integration process, we are enthusiastic about her vision to ensure Noble’s continued growth and future success.”
Sonavex, Inc., a privately held medical device company dedicated to improving surgical patient outcomes with point-of-care imaging technologies, announced that it received $3 million in recent financing, including the $2.2M first close of its Series A round. The offering, led by Grey Sky Venture Partners, was recently expanded by another $1.3 million following increased demand from investors. Other participating investors include CRCM Venture Capital, TEDCO, the Abell Foundation, medical device executives, surgeons, and successful business executives.
Apply for up to $3M to support continued development of your Phase II SBIR or STTR-funded heart, lung, blood, or sleep technology requiring approval or clearance by a Federal regulatory agency. The National Heart, Lung, and Blood Institute (NHLBI) SBIR Phase IIB Bridge and Small Market Awards programs aim to de-risk your technology and encourage partnerships between small businesses and investors and strategic partners.
Portable retinal imager developer Vasoptic Medical raised $1.5 million in a new round of equity financing, according to an SEC filing posted last week.
The Baltimore, Md.-based company is developing a portable retinal imaging device designed to capture physiological information from the retinal microvasculature.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the appointment of Tom Polen, 43, as president of BD, effective immediately. In his new role, Mr. Polen will oversee all of BD’s operating segments – the Medical and Life Sciences segments, as well as the new Interventional segment, which will include the C. R. Bard, Inc. (NYSE: BCR) businesses following the close of BD’s acquisition of Bard, which was also announced today. Mr. Polen, currently executive vice president and president of the BD Medical Segment, will continue to report to Vince Forlenza, who remains chairman and CEO of BD.
U.S. medical equipment supplier Becton Dickinson and Co will acquire C R Bard Inc, in a $24 billion cash-and-stock deal, adding Bard’s devices to its portfolio in the high-growth sectors of oncology and surgery, both companies said on Sunday.
The deal comes two years after Becton Dickinson acquired CareFusion Corp for $12 billion. It is the latest in a string of deals in the medical technology sector, as manufacturers turn to acquisitions to boost profit margins.
John Kilbourne, professor at Grand Valley State U., in Allendale, Mich., came to the March for Science in Washington, D.C., dressed as Galileo, the founder of modern physics and astronomy who was persecuted for standing by his scientific findings.
